←
Dan YEOH688 posts
Dan YEOH avatar

Dan YEOH

@danyeoh

Paeds ID Doc

◷ Joined December 2016▧ 45 Photos and videos
The Infection Flagship, MCRI, Melbourne avatar
⟳ Dan YEOH retweeted
The Infection Flagship, MCRI, Melbourne@Infection_MCRI·16 Aug 2024

Nice review from @danyeoh and @gabhaeusler highlighting >10% of children with AML develop fungal infections, and prophylaxis with novel therapies. Triazoles are the mainstay but newer agents have distinct advantages for children pubmed.ncbi.nlm.nih.gov/3911… @MCRI_for_Kids @ANZPID #AMS

Michelle Yong avatar
⟳ Dan YEOH retweeted
Michelle Yong@michyong2·20 Jun 2023

Just published! Large Australian cohort of #COVID19 affecting cancer patients. A big team effort… showing decreasing severity and all cause mortality over time. @NCICancer @victoriahall26 @BeaCereus @benwteh @NCAS_Aus @monicaslavin doi.org/10.1016/j.lanwpc.202…

Post attachmentPost attachment

Pleased to share our work @NCICancer - largest 🇦🇺 #COVID-19 in #cancer pts cohort to date @LancetRH_WPac. From 2020-2022, severity ⬇️; omicron 🦠 a/c w/ ⬇️ odds of O2, age/male/no OP Rx ⬆️ odds of O2. Big thanks to all involved & PhD supervisors @benwteh @michyong2 @monicaslavin

The Infection Flagship, MCRI, Melbourne avatar
⟳ Dan YEOH retweeted
The Infection Flagship, MCRI, Melbourne@Infection_MCRI·26 May 2023

With the current surge of severe #StrepA/GAS #infections in children worldwide, a timely article by @Infection_MCRI member Dr @JoshOsowicki published in @JIDJournal - this article definitely should be a contender for 'Title of the Year'! @MCRI_for_kids 👏academic.oup.com/jid/article…

Christopher Blyth avatar
⟳ Dan YEOH retweeted
Christopher Blyth@ChrisBlyth74·12 Apr 2023

Led by PhD candidate/ID physician @danyeoh, an opportunity to harness the collective experience in diagnosing invasive pulmonary aspergillosis in Australian children - Timely diagnosis is key to improving outcomes @brendanmcID @monicaslavin @gabhaeusler link.springer.com/article/10…

Thomas Christie Williams avatar
⟳ Dan YEOH retweeted
Thomas Christie Williams@Williams_T_C·30 Sep 2022

3. The ground is shaking beneath our feet- huge changes post-pandemic in RSV seasonality AND importantly susceptibility at @JohnsHopkins essentially no children under 17 months of age with RSV neutralising antibody!

NCAS_Australia avatar
⟳ Dan YEOH retweeted
NCAS_Australia@NCAS_Aus·30 Sep 2022

BREAKING: Very exciting news for our Hospital National Antimicrobial Prescribing Survey users. We have launched the Antifungal NAPS "deep dive" audit! Participate in the first national Antifungal NAPS audit and benchmark the quality of antifungal use in your patient population.

Post attachmentPost attachment
Jake Scott, MD avatar
⟳ Dan YEOH retweeted
Jake Scott, MD@jakescottMD·31 Aug 2022

Timely study from @NIH by Drs Susan Moir, Clarisa Buckner, Lela Kardava & colleagues “When the interval [between infection & booster] is too short, the response induced by the recent infection appears to prevent B cells from responding to the subsequent booster vaccine…”

.@profshanecrotty was right again Recent SARS-CoV-2 infection abrogates antibody and B-cell responses to booster vaccination medrxiv.org/content/10.1101/…

Post attachment
NEJM avatar
⟳ Dan YEOH retweeted
NEJM@NEJM·31 Aug 2022

Conventional wisdom is that previous infection with omicron subvariant BA.1 or BA.2 does notprotect against BA.5, but data from Portugal show considerable protection against BA.5 infection from previous BA.1 or BA.2 infection. nej.md/3pVDLxz

Post attachment
Antibiotic Steward Bassam Ghanem 🅱️C🆔🅿️🌟 avatar
⟳ Dan YEOH retweeted
Antibiotic Steward Bassam Ghanem 🅱️C🆔🅿️🌟@ABsteward·12 Aug 2022

This is intriguing!! Mycoplasma pneumoniae beyond the #COVID19 pandemic: where is it? #IDtwitter #medtwitter #TwitteRx #MedEd thelancet.com/journals/lanmi…

Clinical Infectious Diseases avatar
⟳ Dan YEOH retweeted
Clinical Infectious Diseases@CIDJournal·10 Aug 2022

Infectious Diseases Society of America Guidance on the Treatment of AmpC β-Lactamase–Producing Enterobacterales, Carbapenem-Resistant Acinetobacter baumannii, and Stenotrophomonas maltophilia Infections 🆓 Freely Available 🔗 https://t.co/H5H6y5obGN

Post attachment
Dan YEOH avatar
Dan YEOH@danyeoh·21 Jul 2022

😐 Evusheld 60-fold ⬇️ in neutralisation vs BA.5 ✅ Bebtelovimab retains neutralising activity vs BA.5 (not available outside US 🙁) ✅ Antivirals (remdesivir, molnupiravir, paxlovid) retain activity vs BA.5 ❌ Other monoclonal a/bs still dead in the water

🆕⚡⚡@NEJM Efficacy of Monoclonal Antibodies and Antiviral Drugs against Omicron BA.2.12.1, BA.4, and BA.5 Subvariants Bebtelovimab, Evusheld, Paxlovid, Molnupiravir, Remdesivir, others #IDTwitter nejm.org/doi/full/10.1056/NE…

Post attachment